Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Your healthcare provider will monitor levels and adjust dosing to maintain optimal ranges without over-supplementation
Laboratory studies demonstrate that the peptide was engineered as a fusion with HIV-TAT, a basic and hydrophilic sequence that enables energy-independent cellular uptake, ensuring effective intracellular delivery for precise molecular targeting in experimental settings
Dyslipidemia, a common comorbidity of non-alcoholic fatty liver disease (NAFLD), is reported in approximately 20% to 80% of affected individuals
It has not been approved as a standalone drug by the FDA, placing it in the same regulatory category as most research peptides available through compounding under prescriber supervision
